Lappe Mark — SEC insider filings
SEC reporting owner CIK 1366074. 16 insider filings on record with FilingPulse; latest filed 2026-10-14.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2021-01-19 to 2026-10-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 27 legs across 7 filings — 209,040 shares, $6,908,472 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 17 legs across 5 filings — 104,060 shares, $2,821,140 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: purchase of 9,681 shares @ $112.28 ($1,087,001) in Inhibrx Biosciences, Inc., filed 2026-09-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Chief Executive Officer, Director | 8 | 27 legs · 209,040 sh · $6,908,472 | — | 4 |
| Inhibrx, Inc. (INBX) | Chief Executive Officer, Director | 8 | — | 17 legs · 104,060 sh · $2,821,140 | 9 |
Insider filings — Lappe Mark
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-14 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 2,470 @ $84.07 · Purchase (P): 2,470 @ $85.00 · Purchase (P): 100 @ $85.76 · Purchase (P): 2,449 @ $84.07 · Purchase (P): 2,451 @ $85.00 · Purchase (P): 100 @ $85.76 | EDGAR |
| 2026-09-28 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 3,324 @ $98.87 · Purchase (P): 2,176 @ $99.60 · Purchase (P): 1,500 @ $98.88 · Purchase (P): 3,000 @ $101.70 | EDGAR |
| 2026-09-08 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 5,895 @ $99.29 · Purchase (P): 6,605 @ $100.64 · Purchase (P): 1,100 @ $107.12 · Purchase (P): 500 @ $108.23 · Purchase (P): 1,219 @ $111.88 · Purchase (P): 9,681 @ $112.28 | EDGAR |
| 2024-09-16 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 26,963 @ $15.05 · Purchase (P): 13,037 @ $17.13 | EDGAR |
| 2024-09-10 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 26,000 @ $15.29 · Purchase (P): 9,500 @ $15.21 · Purchase (P): 8,500 @ $15.19 | EDGAR |
| 2024-09-03 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 10,000 @ $14.03 · Purchase (P): 10,000 @ $14.02 · Purchase (P): 15,288 @ $15.66 · Purchase (P): 4,712 @ $16.31 | EDGAR |
| 2024-08-22 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 27,055 @ $12.97 · Purchase (P): 12,945 @ $12.93 | EDGAR |
| 2024-05-30 | 4 | Inhibrx, Inc. (INBX) | Disposition to issuer (D): 2,486,192 @ $30 · Disposition to issuer (D): 500,000 @ $30 · Disposition to issuer (D): 59,462 @ $30 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 145,000 (derivative) | EDGAR |
| 2024-05-30 | 4 | Inhibrx Biosciences, Inc. (INXB) | Grant/award (A): 621,548 · Grant/award (A): 125,000 · Grant/award (A): 14,865 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2023-03-01 | 4 | Inhibrx, Inc. (INBX) jointly with Lappe Family Trust | Sale (S): 60 @ $25.02 | EDGAR |
| 2023-01-24 | 4 | Inhibrx, Inc. (INBX) jointly with Lappe Family Trust | Sale (S): 21,665 @ $25.36 · Sale (S): 4,272 @ $25.71 · Sale (S): 63 @ $26.11 | EDGAR |
| 2023-01-03 | 4 | Inhibrx, Inc. (INBX) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-12-20 | 4 | Inhibrx, Inc. (INBX) jointly with Lappe Family Trust | Sale (S): 25,246 @ $25.53 · Sale (S): 754 @ $26.29 | EDGAR |
| 2022-11-18 | 4 | Inhibrx, Inc. (INBX) jointly with Lappe Family Trust | Sale (S): 6,959 @ $25.36 · Sale (S): 4,106 @ $26.57 · Sale (S): 4,333 @ $27.45 · Sale (S): 1,767 @ $28.86 · Sale (S): 6,773 @ $30.15 · Sale (S): 912 @ $30.67 · +1 more | EDGAR |
| 2022-10-18 | 4 | Inhibrx, Inc. (INBX) jointly with Lappe Family Trust | Sale (S): 8,981 @ $28.66 · Sale (S): 14,006 @ $29.92 · Sale (S): 2,892 @ $30.81 · Sale (S): 121 @ $31.51 | EDGAR |
| 2021-01-19 | 4 | Inhibrx, Inc. (INBX) jointly with Lappe Family Trust | Gift (G): 500,000 @ $0 · Gift (G): 500,000 @ $0 · Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1366074 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs